- Home
- MCY vs PTGX Comparison
MCY vs PTGX Comparison
Compare MCY & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCY | PTGX |
|---|---|---|
| Founded | 1961 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.1B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | MCY | PTGX |
|---|---|---|
| Price | $93.46 | $80.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $100.00 | $99.20 |
| AVG Volume (30 Days) | 206.2K | ★ 897.9K |
| Earning Date | 02-17-2026 | 02-20-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.93 | 0.72 |
| Revenue | ★ $5,814,768,000.00 | $209,217,000.00 |
| Revenue This Year | $10.03 | N/A |
| Revenue Next Year | $4.40 | $409.41 |
| P/E Ratio | ★ $11.56 | $115.66 |
| Revenue Growth | ★ 5.93 | N/A |
| 52 Week Low | $47.06 | $33.70 |
| 52 Week High | $96.50 | $96.54 |
Technical Indicators
Market Signals| Indicator | MCY | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 63.07 | 42.61 |
| Support Level | $83.83 | $77.70 |
| Resistance Level | $87.88 | $86.10 |
| Average True Range (ATR) | 2.50 | 3.64 |
| MACD | 0.64 | 0.07 |
| Stochastic Oscillator | 93.77 | 32.44 |
Price Performance
Historical ComparisonAbout MCY Mercury General Corporation
Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The Company offers the following types of automobile coverage: collision, property damage, bodily injury ("BI"), comprehensive, personal injury protection ("PIP"), underinsured and uninsured motorist, and other hazards. The Company offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.